###### Strengths and limitations of this study

-   Large sample of patients who underwent upper and lower extremities amputation.

-   This study used microcosting and case-mix group methods for healthcare cost analysis.

-   There is a lack of information about the cost of outpatient care and rehabilitation services.

-   All amputations were performed in the only tertiary centre in Qatar (2000--2014).

-   The study focused mainly on diagnostic and therapeutic costs but did not include indirect costs.

Introduction {#s1}
============

Limb amputation remains a major problem worldwide in spite of the advancement in the diagnostic and therapeutic measures. In the USA, 1.6 million people were estimated to be living with limb loss in 2005, of them 65% had lower extremity amputation (LEA).[@R1] However, upper extremity amputation (UEA) is relatively rare (8%) and mostly related to traumatic injury (68.6%).[@R1]

According to the recent WHO estimates, around 150 million individuals are affected by diabetes mellitus (DM) globally; and this figure is expected to be twofold by the year 2025.[@R2] The risk of LEA is considerably higher (10-fold) in patients with DM as compared with non-diabetics.[@R3] Nearly, 75% of the LEAs are performed in the patients with diabetic foot disease.[@R4] Also, LEA is associated with higher risk of mortality, impaired quality of life and increased healthcare costs among diabetics.[@R6] Early initiatives perused the goal to reduce the number of LEAs in patients with diabetes.[@R7] However, epidemiological studies have shown marked variations in the incidence, relative risks and time trends and management of LEA in diabetic compared with non-diabetic population, owing to differences in study design and methodological approaches.[@R5]

Furthermore, the treatment strategies of LEA should carefully account for the associated complications, quality of life and healthcare cost. Lower Extremity Assessment Project study revealed similar functional outcomes in patients underwent amputation or reconstruction of the limb-threatening lower extremity injury.[@R10] An earlier meta-analysis, based on nine observational studies also found no significant difference in terms of functional outcome of patients with leg-threatening injuries treated either with limb salvage or primary amputation on follow-up.[@R11] It has been suggested that the functional outcomes are often improved after successful limb reconstruction in comparison to early amputation and appropriate prosthesis.[@R12] Also, some studies concluded that the cost of amputation is less as compared with limb salvage and early amputation is a reasonable cost-effective strategy.[@R11] Although, reconstructive limb salvage is technically challenging and time-consuming, some investigators suggested that it is associated with improved quality of life and lesser costs of treatment as compared with amputation.[@R15] Notably, in Qatar the prevalence of diabetes is rapidly increasing with an escalating problem of diabetic foot disorder that necessitates amputation.[@R17] Currently, there is a lack of integrated facility to treat diabetic foot ulceration which may compromise the quality of life, with lower productivity, higher medical cost and unnecessary amputations. Therefore, cost of illness (COI) analysis for diabetics and non-diabetics is imperative to provide the scientific evidence for making appropriate clinical decisions, cost-saving and resource allocation. In addition, it could be beneficial for improvement in preventative diabetic foot care, avoidance of unfavourable outcomes and will be a basis for formulation of health policies and fiscally sound decisions to improve healthcare facilities. Considering the expanding need and limitation of healthcare resource, this study presents the healthcare costs of amputation and prosthesis for management of upper and lower extremities in a tertiary healthcare institution of Qatar.

Methods {#s2}
=======

Study population and settings {#s2a}
-----------------------------

It was a retrospective cohort study based on data obtained from the operating theatre database and medical records at Hamad General Hospital (HGH) for all patients who underwent UEA and LEA between 2000 and 2014. Median follow-up time was 19 with an IQR of 3--53 months. All patients with major and minor amputation were included in the study. Primary healthcare and tertiary referral care centres comprised the healthcare system in Qatar. HGH is the referral hospital that provides basic healthcare facilities to manage high-risk patients for amputation who require elective and emergency surgery including trauma and vascular management. During the study period, there was no provision of health insurance scheme and all emergency services were provided free of cost to patients. Both nationals and expatriates with valid resident permit used to have equal access to health facilities. All in-hospital diagnostic and therapeutic services are available free of charge at HGH for all nationals and residents in Qatar, whereas costs of prosthesis are covered by private or charity agencies for residents. HGH is the only tertiary hospital in Qatar performing amputations during the study period.

Data collection {#s2b}
---------------

Data were collected on patient demographic characteristics (age, gender and nationality), DM status, intervention details (indications, level of amputation, major and minor amputation) and part (limb or digit) amputated, length of hospital stay and early mortality. We obtained data for the cost of amputation and hospitalisation according to the level of the amputation (toe, finger, forefoot/hind foot, above/below knee, wrist level, above/below elbow) and cost per bed days. The procedure and material cost was included in the level of amputation cost.

The sessions were categorised as major amputations, which involved below-knee and above-knee amputation, whereas minor amputations referred to the sessions involving digit (toe or finger) and transmetatarsal amputations. Amputations were further classified based on involvement of single or multiple extremities. The major indication for amputation was diabetic foot ulcer with or without ischaemia followed by traumatic injury and tumour. The diagnosis of DM was considered based on patient's history of diabetes and/or current antidiabetic management such as insulin therapy and oral hypoglycaemic agent.

### Patient and public involvement {#s2b1}

Patients and public were not involved in this study, because it is a retrospective cohort study and data were collected anonymously.

Cost analysis {#s2c}
-------------

COI studies are needed for justification of budget, establishment of preventive and interventional programmes and setting up priorities for research funding by healthcare policy makers.[@R4] Depending on the objective of cost analysis, it can be either based on prevalence or incidence of the disease. Prevalence is more commonly considered for budget planning and decision making by health policy makers.[@R18] This includes calculation of total costs for a study population over particular period of time in a specified area.[@R18] For health economics research, medical costs and disease-associated costs are the two main criteria considered for cost evaluation.[@R19] These medical costs are further subclassified as direct (types of payments and expenses) and indirect (resource utilisation).[@R19] The direct cost involves costs incurred for in-hospital and outpatient services, medical supplies, laboratory investigations, medication, rehabilitation services at care centres, home and caregiver costs. Costs of resources that are lost due to morbidity and mortality referred as indirect costs.[@R19]

Overall cost=amputation cost+hospital stay cost+prosthesis cost+angiography alone cost+angiography/angioplasty cost+angiography/angioplasty/stent cost+bypass for peripheral artery disease cost+diabetic foot ulceration cost+haemodialysis cost+peritoneal dialysis cost.

The cost of amputation and hospitalisation were calculated using a microcosting methodology, whereas the prosthesis and therapeutic cost were calculated using case-mix group method. This study includes all amputation cases data from a national tertiary centre for a period of 14 years. It also addresses an overview of the clinical progress of a 14-year amputee population. By following this cohort from their initial procedure until rehabilitation, leaving the country or mortality, it provides the reader with valuable insights into the demographic pattern, risk factors, clinical presentation, economic burden, management and outcomes.

### Evaluation of amputation costs {#s2c1}

The total medical cost of upper and lower limb amputation was calculated by multiplying the number of amputations, hospital stays, prosthesis and therapeutic interventions with the respective unit costs. [Figure 1](#F1){ref-type="fig"} shows the overview of total medical cost analysis. The direct medical costs were also computed for amputations, hospital stays and prosthesis. The direct related (therapeutic) medical cost evaluation in this study mainly comprised procedural cost involving angiography, angiography/angioplasty, angiography/angioplasty/stent, bypass for peripheral artery disease, management cost of diabetic foot ulceration, haemodialysis and peritoneal dialysis. All costs are represented in US dollars.

![Overview of total medical cost analysis flow diagram.](bmjopen-2018-024963f01){#F1}

The institutional medical cost was obtained from the '*Estimated Cost of Service---Summary'*, cost accounting section, finance department, Hamad Medical Corporation, Doha, Qatar ([table 1](#T1){ref-type="table"}).

###### 

Estimated cost of service---summary

  Procedure                               Cost (in US\$)
  --------------------------------------- ----------------
  Level of amputation                     
   Toe                                    2068
   Finger                                 2169
   Forefoot/hind foot                     10 639
   Above/below knee                       10 639
   Wrist level                            10 639
   Above/below elbow                      10 639
  Per bed days                            1236
  Prosthesis                              
   Prosthesis fabrication                 6415
   Fitting of prosthesis and training     736.3
   Total cost for prosthesis              7151
  Therapeutic                             
   Angiography                            684
   Angiography-angioplasty                1033
   Angiography-angioplasty-stent          2398
   Bypass for peripheral artery disease   3115
   Diabetic foot ulceration               553 845
   Haemodialysis                          341
   Peritoneal dialysis                    640

Data management and statistical analysis {#s2d}
----------------------------------------

Descriptive and inferential statistics were applied for data analysis. Cost estimates are presented as point estimates with 95% CIs, which were used to generalise the percentages. Linear regression analysis and scatter plot were used to find out the correlation between variables. Data were analysed using R V.3.5.1 and Statistical Package for the Social Sciences (SPSS) for Windows V.21.0 (SPSS, Chicago, Illinois, USA).

Result {#s3}
======

Sociodemographic characteristics {#s3a}
--------------------------------

A total of 871 patients underwent 1102 (major 357 and minor 745) upper and lower extremities amputation over the 14-year study duration. The mean age of patients was 59.4±18.3, 77.2% (95% CI 74.25 to 79.82) were males and 37.4% were citizens ([table 2](#T2){ref-type="table"}). Amputations were most frequent in the age group \>60 years (51.1%) followed by 41--60 years (33.2%) and ≤40 years (15.7%). The majority of patients (75.9%, 95% CI 72.91% to 78.59%) were diabetics. The most common indication for amputation was diabetic foot complications (74.8%), followed by trauma (18.9%) and ischaemia (5.6%).

###### 

Comparison of amputation and hospital stay cost stratified by demographics, aetiology and early mortality (n=871) in US\$

  Age group (years)              n (%)         Total amputation cost   Mean (95% CI)               Total hospital stay cost   Mean (95% CI)
  ------------------------------ ------------- ----------------------- --------------------------- -------------------------- ---------------------------
   ≤40                           137 (15.7%)   882 090                 6439 (5662 to 7215)         5 378 984                  39 263 (31 984 to 46 542)
   41--60                        289 (33.2%)   1 678 534               5808 (5128 to 6488)         11 503 434                 39 804 (35 327 to 44 281)
   \>60                          445 (51.1%)   3 581 747               8049 (7435 to 8663)         28 572 528                 64 208 (45 873 to 82 543)
  Gender                                                                                                                      
   Female                        199 (22.8%)   1 589 342               7987 (7114 to 8859)         10 389 560                 52 209 (34 804 to 69 614)
   Male                          672 (77.2%)   4 553 028               6775 (6311.9 to 7239)       35 065 385                 52 181 (40 787 to 63 424)
  Nationality                                                                                                                 
   Non-Qatari                    545 (62.6%)   3 330 736               6112 (5635 to 6588)         25 933 104                 47 584 (35 773 to 59 394)
   Qatari                        326 (37.4%)   2 811 634               8625 (7902 to 9348)         19 521 841                 59 883 (43 415 to 76 088)
  Diabetes                                                                                                                    
   No                            210 (24.1%)   1 524 925               7262 (6553.6 to 7970)       10 620 742                 50 575 (35 498 to 65 652)
   Yes                           661 (75.9%)   4 617 445               6985 (6494 to 7478)         34 834 203                 52 699 (40 924 to 64 323)
  Early mortality                                                                                                             
   No                            822 (94.4%)   5 571 740               6778 (6361 to 7196)         42 737 637                 51 992 (42 005 to 61 856)
   Yes                           49 (5.6%)     570 630                 11 646 (10 099 to 13 192)   2 717 308                  55 455 (18 509 to 92 402)
  Aetiology                                                                                                                   
   Diabetic foot                 485 (55.7%)   2 931 285               6043 (5546 to 6542)         24 795 742                 51 125 (36 743 to 65 507)
   Ischaemia                     49 (5.6%)     400 219                 8168 (6662 to 9674)         2 664 148                  54 370 (38 091 to 70 649)
   Injury                        165 (18.9%)   1 171 397               7099 (6346 to 7853)         6 963 874                  42 205 (34 177 to 50 234)
   Diabetic foot and ischaemia   166 (19.1%)   1 578 003               9506 (8271 to 10 741)       10 757 967                 64 807 (38 704 to 90 910)
   Tumour                        4 (0.5%)      48 759                  12 190 (0 to 27 620)        176 786                    44 196 (3329 to 85 064)
   Congenital deformity          1 (0.1%)      10 639                  10 638                      48 214                     48 214
   Lizard bite                   1 (0.1%)      2068                    2068                        48 214                     48 214

Cost analysis {#s3b}
-------------

Analysis of the cost of amputation and hospital stay stratified by sociodemographic factors, aetiology and early mortality are shown in [table 2](#T2){ref-type="table"}. The total and mean amputation and hospital stay cost were highest for elderly patients (\>60 years) as compared with other age groups. However, females, Qatari nationals and patients with no diabetes were more likely to have higher mean amputation and hospital stay cost even though the total cost was more in their counterparts. Also, early mortality accounted for higher mean cost of amputation and hospital stay but the total cost for both was relatively lower as compared with those who survived.

[Table 3](#T3){ref-type="table"} shows analysis of the cost of amputation according to level of amputation. A total of 357 patients underwent major amputations in the index admission and on follow-up with an estimated total cost of US\$3 797 931 and 745 patients required minor amputations which were estimated to cost US\$2 344 439. As per the level of amputation, below-knee (n=172) and above-knee (n=164) amputations involved in maximum cost with a total estimate of US\$1 829 815 and US\$1 744 708, respectively.

###### 

Analysis of cost of amputation according to level of amputation in the index admission and on follow-up in US\$

  Follow-up                  First admission   Second admission   Third admission   Fourth admission   Fifth admission   Sixth admission   Seventh admission   Total                                                                                                                
  -------------------------- ----------------- ------------------ ----------------- ------------------ ----------------- ----------------- ------------------- ----------- -------- ---- ---------- -------- ---- ---------- -------- ---- -------- -------- ---- -------- -------- -----------
  Toe (n=671)                573               1 330 060          2322              71                 1 69 609          2389              19                  57 915      3048     6    12 410     2068     2    4136       2068     --   --       --       --   --       --       1 574 132
  Forefoot (n=68)            39                4 14 900           10 639            15                 1 59 577          10 639            10                  1 06 385    10 639   3    3 19 159   10 639   --   --         --       1    10 639   10 639   --   --       --       7 23 415
  Hind foot (n=4)            4                 42 554             10 639            --                 --                --                --                  --          --       --   --         --       --   --         --       --   --       --       --   --       --       42 554
  Below knee (n=172)         118               1 255 339          10 639            37                 3 93 623          10 639            7                   74 469      10 639   6    63 831     10 639   3    3 19 157   10 639   --   --       --       1    10 639   10 639   1 829 815
  Above knee (n=164)         114               1 212 785          10 639            40                 4 25 539          10 639            4                   42 554      10 639   4    42 554     10 639   2    21 277     10 639   --   --       --       --   --       --       1 744 708
  Finger (n=2)               2                 4339               2170              --                 --                --                --                  --          --       --   --         --       --   --         --       --   --       --       --   --       --       4339
  Wrist level (n=6)          6                 63 831             10 639            --                 --                --                --                  --          --       --   --         --       --   --         --       --   --       --       --   --       --       63 831
  Below elbow (n=5)          5                 53 192             10 639            --                 --                --                --                  --          --       --   --         --       --   --         --       --   --       --       --   --       --       53 192
  Above elbow (n=10)         10                1 06 385           10 639            --                 --                --                --                  --          --       --   --         --       --   --         --       --   --       --       --   --       --       1 06 385
  Type of amputation                                                                                                                                                                                                                                                                
  Major amputation (n=357)   253               2 691 531          10 639            77                 8 19 162          10 639            11                  1 170 239   10 639   10   1 06 385   10 639   5    5 31 927   10 639   --   --       --       1    10 639   10 639   3 797 931
  Minor amputation (n=745)   618               1 791 852          2900              86                 3 29 186          3828              29                  1 64 300    5666     9    44 326     4925     2    4137       2069     1    10 639   10 639   --   --       --       2 344 439
  Total (n=1102)             871               4 483 383                            163                1 148 348                           40                  2 813 239            19   1 50 710            7    57 329              1    10 639            1    10 639            6 142 370

[Table 4](#T4){ref-type="table"} represents the estimated cost of hospital stay according to the level of amputation. For major and minor amputations, the hospital cost was estimated to be US\$21 351 511 and US\$24 103 434, respectively. Toe amputations incurred maximum total cost (US\$21 454 121) followed by above-knee (US\$13 778 159) and below-knee (US\$6 815 522) amputations.

###### 

Comparison of cost of hospital stays for amputation according to level of amputation in the index admission and on follow-up in US\$

  Follow-up                  First admission   Second admission   Third admission   Fourth admission   Fifth admission   Sixth admission   Seventh admission   Total                                                                                                    
  -------------------------- ----------------- ------------------ ----------------- ------------------ ----------------- ----------------- ------------------- ---------- -------- ---- ---------- -------- --- ---------- -------- --- ------ ------ --- ------ ------ ------------
  Toe (n=671)                573               19 191 758         33 493            71                 1 509 478         21 260            19                  5 61 264   29 540   6    1 64 423   27 404   2   27 198     13 599                                       21 454 121
  Forefoot (n=68)            39                1 485 989          38 102            15                 6 15 659          41 044            10                  1 82 967   18 297   3    1 40 934   46 978                           1   6181   6181                     2 431 731
  Hind foot (n=4)            4                 1 86 676           46 669                                                                                                                                                                                                1 86 676
  Below knee (n=172)         118               5 671 978          48 068            37                 8 23 352          22 253            7                   76 648     10 950   6    1 79 258   29 876   3   54 396     18 132                     1   9890   9890   6 815 522
  Above knee (n=164)         114               12 507 280         1 09 713          40                 1 084 203         27 105            4                   87 775     21 944   4    39 560     9890     2   59 341     29 670                                       13 778 159
  Finger (n=2)               2                 30 907             15 453                                                                                                                                                                                                30 907
  Wrist level (n=6)          6                 2 33 654           38 942                                                                                                                                                                                                2 33 654
  Below elbow (n=5)          5                 2 17 582           43 517                                                                                                                                                                                                2 17 583
  Above elbow (n=10)         10                3 06 593           30 659                                                                                                                                                                                                3 06 593
  Total (n=1102)             871               39 832 418         45 732            163                4 032 692         24 740            40                  9 08 654   22 717   19   5 24 176   27 588   7   1 40 934   20 134   1   6181   6181   1   9890   9890   45 454 945
  Type of amputation                                                                                                                                                                                                                                                    
  Major amputation (n=357)   253               18 937 088         74 850            77                 1 907 555         24 773            11                  1 64 423   14 948   10   2 18 819   21 882   5   1 13 736   22 747   0                 1   9890   9890   21 351 511
  Minor amputation (n=745)   618               20 895 330         33 811            86                 2 125 137         24 711            29                  7 44 231   25 663   9    3 05 357   33 929   2   27 198     13 599   1   6181   6181   0                 24 103 434

The cumulative direct healthcare cost comprised the total cost of all amputations US\$6 142 370 (mean: 7052; 95% CI 6642 to 7462), total bed days cost US\$45 454 945 (mean: 52 187; 95% CI 42 618 to 61 756) and total prosthesis cost (n=74) US\$529 181. Therefore, the total direct healthcare cost was estimated to be US\$52 126 496, and per patient direct healthcare cost was found to be US\$59 846.

[Table 5](#T5){ref-type="table"} represents the estimated total cost (amputation cost+hospital stay cost) according to the level of amputation. For major and minor amputations, the hospital cost was estimated to be US\$25 149 442 and US\$26 447 873, respectively.

###### 

Analysis of total cost (amputation+hospital stay) according to level of amputation in the index admission and on follow-up in US\$

  Follow-up                  First admission   Second admission   Third admission   Fourth admission   Fifth admission   Sixth admission   Seventh admission   Total                                                                                                             
  -------------------------- ----------------- ------------------ ----------------- ------------------ ----------------- ----------------- ------------------- ----------- -------- ---- ---------- -------- --- ---------- -------- --- -------- -------- --- -------- -------- ------------
  Toe (n=671)                573               20 521 818         35 815            71                 1 679 087         23 649            19                  6 19 179    32 588   6    1 76 833   29 472   2   31 334     15 667                                               23 028 253
  Forefoot (n=68)            39                1 900 889          48 741            15                 7 75 236          51 683            10                  2 89 352    28 936   3    4 60 093   57 617                           1   16 820   16 820                         3 155 146
  Hind foot (n=4)            4                 2 29 230           57 308                                                                                                                                                                                                         2 29 230
  Below knee (n=172)         118               6 927 317          58 707            37                 1 216 975         32 892            7                   1 51 117    21 589   6    2 43 089   40 515   3   3 73 553   28 771                         1   20 529   20 529   8 645 337
  Above knee (n=164)         114               13 720 065         1 20 352          40                 1 509 742         37 744            4                   1 30 329    32 583   4    82 114     20 529   2   80 618     40 309                                               15 522 867
  Finger (n=2)               2                 35 246             17 623                                                                                                                                                                                                         35 246
  Wrist level (n=6)          6                 2 97 485           49 581                                                                                                                                                                                                         2 97 485
  Below elbow (n=5)          5                 2 70 774           54 156                                                                                                                                                                                                         2 70 775
  Above elbow (n=10)         10                4 12 978           41 298                                                                                                                                                                                                         4 12 978
  Type of amputation                                                                                                                                                                                                                                                             0
  Major amputation (n=357)   253               21 628 619         85 489            77                 2 726 717         35 412            11                  1 334 662   25 587   10   3 25 204   32 521   5   6 45 663   33 386   0                     1   20 529   20 529   25 149 442
  Minor amputation (n=745)   618               22 687 182         36 711            86                 2 454 323         28 539            29                  9 08 531    31 329   9    3 49 683   38 854   2   31 335     15 668   1   16 820   16 820   0                     26 447 873
  Total (n=1102)             871               44 315 801         45 732            163                5 181 040         24 740            40                  3 721 893   22 717   19   6 74 886   27 588   7   1 98 263   20 134   1   16 820   16 820   1   20 529   20 529   51 597 315

[Table 6](#T6){ref-type="table"} demonstrated the estimation of direct related therapeutic interventions cost of amputation. The total direct related therapeutic interventions cost was estimated to be US\$26 096 046. Haemodialysis (US\$515 495), management of diabetic foot ulceration (US\$24 590 940) and peritoneal dialysis (US\$677 120) accounted for the major direct therapeutic cost.

###### 

Direct related therapeutic interventions cost of amputation in US\$

                                          Cost     Frequency (n)   Total length of hospital stay (days)   Total cost
  --------------------------------------- -------- --------------- -------------------------------------- ------------
  Therapeutic interventions                                                                               
   Angiography alone                      684      86              --                                     58 824
   Angiography-angioplasty                868      70              --                                     60 760
   Angiography-angioplasty-stent          2398     9               --                                     21 582
   Bypass for peripheral artery disease   3115     55              --                                     171 325
   Diabetic foot ulceration               55 385   444             --                                     24 590 940
   Haemodialysis                          341      132             5291                                   515 495
   Peritoneal dialysis                    640      25              1058                                   677 120
  Total                                   --       --              --                                     26 096 046

Regression analysis {#s3c}
-------------------

Overall cost=36 458.27+1.02 hospital stay cost

There was a positive strong correlation between overall cost and hospital stay cost (r^2^=0.96, p=0.00001). Other variables showed a weak correlation (r^2^\<0.30). Hospital stay cost was an independent predictor of overall cost. [Figure 2](#F2){ref-type="fig"} depicts the correlation between overall cost and the regression adjusted predicted value.

![Scatter plot of the overall cost and regression adjusted predicted value.](bmjopen-2018-024963f02){#F2}

Discussion {#s4}
==========

To the best of our knowledge, this is the first study on healthcare cost associated with amputation and prosthesis in the Arab Middle East region. We estimated the association between patient demographics, characteristics, DM, mortality and direct medical costs of upper and lower extremities amputation managed at a tertiary care institution over 14 years. Despite some limitations, the present study attempts to estimate the economic burden of extremity amputation on the healthcare system. The study revealed that the total direct healthcare cost of amputation per patient in Qatar was US\$89 808. The expected management cost is considerable and varies according to patients characteristics.

In the present study, the mean age of patients was 59 years and amputations were performed mostly among the elderly group. Prior population-based studies reported a mean age of 65 years in patients with LEA.[@R21] Moreover, females, Qatari nationals and patients with no diabetes were more likely to have higher mean amputation and hospital stay cost in our study cohort; however, the total cost of amputation and hospital stay remains higher among males, non-Qataris and diabetics. Lefebvre and Chevan[@R23] suggested that females were more likely to undergo major amputation than males which could be attributed to delayed presentation of women with vascular disease. Furthermore, female usually have a longer time for the diagnosis of DM, and its associated complications which might result in higher costs.[@R24]

The current analysis extends the previous results to demonstrate that the total costs are higher in patients with DM than patients with no diabetes.[@R25]

The global incidence of LEA has dispersion because of population heterogeneity. Even though there is a declining trend over time but the incidence rate of LEA remains high. In our study, 67% of amputations were minor in nature. Globally, there exists a higher incidence of LEA among diabetics which ranges from 46.1 to 9600 per 100 000 population than those without DM (5.8--31 per 100 000 population).[@R26] Similarly, our study showed that the majority of amputations were done in patients with diabetes (75.86%, 95% CI 72.91% to 78.59%). An earlier study reported a high prevalence of DM (16.7%) in adult Qatari population.[@R27] In our study, the mean amputation cost was US\$6985 and mean hospital stay cost was US\$52 699 among diabetics. Brandle *et al* [@R28] found the median cost of an amputation as US\$37 600 (US\$23 300--US\$62 200) in 2003. The present study reported a higher overall total direct healthcare cost of amputation per patient which was found to be US\$59 846. Similar to our estimates, Margolis *et al* [@R29] reported that the mean total annual Medicare payments for any beneficiary with diabetes-related LEA were roughly US\$52 000 in 2008. Rinkel *et al* [@R30] study on patients with diabetic foot disease, revealed an average in-hospital costs to be US\$10 827 (range: 702--82 880) per episode. The average cost of single minor amputation, multiple minor amputations and major amputations were US\$13 580, US\$31 835 and US\$73 813 per episode, respectively. Mundell *et al* [@R31] identified the mean medical costs for transfemoral amputations of hospitalised patients as US\$25 652 (95% CI US\$10 468 to US\$38 872) and emergency department as US\$18 091 (95% CI US\$7820 to US\$57 368). Franklin *et al* [@R32] reported in a study that mean cost of care for patients with diabetes in US veterans with lower limb amputation for all amputation level was US\$60 647 (95% CI US\$59 143 to US\$62 188), for toe was US\$41 484 (95% CI US\$40 075 to US\$42 943), below knee was US\$71 067 (95% CI US\$68 449 to US\$73 785) and above knee was US\$82 758 (US\$78 063 to US\$87 736).

[Table 7](#T7){ref-type="table"} shows the prevalence of DM in the Arab Middle Eastern region ranges from 1.88% to 25.5%.[@R27] Diabetes-related complications could be serious and necessitate prolonged hospitalisation, and in some cases, it might need major surgical intervention. Hospital cost remains the highest cost component for the management of diabetic foot ulceration (DFU). Improvement of the preventive measures and patient management will result in a reduction of total healthcare costs of the related disease. The second leading component of cost is the pharmacy cost. Among these costs, antithrombotic drugs have the largest share. Increased use of generic antithrombotic drugs may be a powerful factor for reducing this cost.

###### 

Prevalence of diabetes and diabetic foot complications in the Arab population

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                      WHO estimates on prevalence of diabetes[@R33]   Prevalence of diabetes mellitus   Prevalence of diabetic foot complications                                             
  ---------------------------- ----------------------------------------------- --------------------------------- ------------------------------------------------------------------------------------- --------------------------------------
  Tunisia[@R34]                1 66 000                                        3 88 000                          9.9% (9.5% in men vs 10.1% in female)\                                                Data not available
                                                                                                                 It doubled in 15-year period                                                          

  Morocco[@R35]                4 27 000                                        1 138 000                         6.6%                                                                                  Data not available

  Algeria[@R36]                Data not available                              Data not available                10.6% (10.8% male vs 10.5% female)                                                    Diabetic foot ulcer 11.9%,\
                                                                                                                                                                                                       Neuropathy 84.85% &\
                                                                                                                                                                                                       Peripheral arteriopathy 78.78%

  Mauritania[@R39]             Data not available                              Data not available                1.88% (1.3% males vs 2.29% female)                                                    Data not available

  Libya[@R40]                  88 000                                          2 45 000                          Data not available                                                                    Peripheral arteriopathy 60% &\
                                                                                                                                                                                                       Neuropathy 40%

  Sudan[@R41]                  4 47 000                                        1 277 000                         8.3% (9.9% male vs 7.5% female)                                                       Neuropathy 37% &\
                                                                                                                                                                                                       PVD10%

  Egypt[@R44]                  2 623 000                                       6 726 000                         2.4% rural area & 8.4% in low socioeconomic class & 10% in high socioeconomic class   Foot ulcer 1% &\
                                                                                                                                                                                                       Diabetic neuropathy 22%

  Somalia[@R46]                97 000                                          3 31 000                          2.3%                                                                                  Data not available

  Djibouti[@R47]               7000                                            9000                              4.1%                                                                                  Data not available

  Yemen[@R48]                  3 27 000                                        1 286 000                         4.6% (7.4% male vs 2% female)                                                         Data not available

  Oman[@R49]                   1 13 000                                        3 43 000                          16.1%                                                                                 Data not available

  United Arab Emirates[@R50]   3 50 000                                        6 84 000                          DM 29.2%, prediabetes 24.2%                                                           Neuropathy 34.7% &\
                                                                                                                                                                                                       PVD 11.1%

  Qatar[@R27]                  38 000                                          88 000                            DM 16.7%, prediabetes 13.8%                                                           Data not available

  Bahrain[@R51]                37 000                                          99 000                            DM 25.5%, prediabetes 14.7%                                                           Neuropathy 36.6%\
                                                                                                                                                                                                       PVD 11.8%\
                                                                                                                                                                                                       Foot ulcer 5.9%

  Kuwait[@R53]                 1 04 000                                        3 19 000                          12.8%                                                                                 Data not available

  Iraq[@R54]                   6 68 000                                        2 009 000                         21.4%                                                                                 Diabetic foot 2.3%,\
                                                                                                                                                                                                       Neuropathy 13%,\
                                                                                                                                                                                                       Amputation 0.7% &\
                                                                                                                                                                                                       PVD 0.2%

  Syria[@R56]                  6 27 000                                        2 313 000                         15.6%                                                                                 Data not available

  Lebanon[@R57]                1 46 000                                        3 78 000                          11.3%                                                                                 PVD 18.3%

  Jordan[@R59]                 1 95 000                                        6 80 000                          17.1%                                                                                 Diabetic foot ulcer 5%,\
                                                                                                                                                                                                       Neuropathy 19% &\
                                                                                                                                                                                                       Amputation 5%

  Saudi Arabia[@R61]           8 90 000                                        2 523 000                         23.7%                                                                                 Peripheral neuropathy 13.7%--35.9%,\
                                                                                                                                                                                                       Diabetic foot 4.3% &\
                                                                                                                                                                                                       Amputation 1.9%

  Palestine[@R64]              Data not available                              Data not available                9.6%                                                                                  Data not available
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PVD, peripheral vascular disease.

Harrington *et al* [@R65] reported the average ulcer-related cost per year to be US\$3609. Our study had 444 patients with DFU, which contributed the average ulcer-related cost per year to be US\$ 3956. Stockl *et al* [@R66] found the average ulcer episode cost as US\$13 179. In our study, the total ulcer episode cost for Qatar was US\$5 851 476. Barceló *et al* [@R67] estimated the cost of permanent disability caused by DM. Similarly, we have attempted to assess the cost of disability using the formulae, 'The estimated cost of permanent disability=number of productive years lost to disability×the per capita gross domestic product (GDP)'. According to the GDP, Qatar comes under the high-income group with a per capita indirect cost of US\$7959 for DM. Based on this, total per capita indirect cost of DM was US\$44 196 327 between the year 2000 and 2014 in our study.

An earlier study from the United Arab Emirates[@R25] reported the annual mean treatment cost to be US\$5645, which is comparatively higher than the estimated cost per patient per year US\$3990 in the present study.

According to the WHO Qatar report 2016, around 38 000 individuals are diagnosed with DM, which is predicted to increase to 88 000 by 2030.[@R33]

Appropriate and efficient treatment of DM could significantly prevent or reduce vascular complications. Therefore, prevention of complication related to DFU is considered as the most effective means of healthcare cost reduction.

Another alternative to minimise the cost is delaying the complication as long as possible. For prevention of DFU, it is useful to train the high-risk patients and to spread awareness among patients with diabetes which have implications for cost savings.[@R68] The present study revealed a high cost of amputation and prosthesis. Findings of our analysis have implications to inform healthcare policy makers about the financial burden of amputations and urge the need for effective planning to improve outcomes of DM in Qatar.

A major limiting factor of the present study is the retrospective nature; therefore, the collected data might have missing information about the exact duration of diabetes. We might have underestimated the total costs as we mainly focused on the direct medical costs and cost of therapeutic interventions but did not include, payments incurred by patient, out-of-pocket costs, direct non-medical costs or other indirect costs.

We could not account pharmacy-related costs separately. The laboratory and radiological investigations, medical supplies and medications that were directly used during the course of treatment, and non-medical direct expenses were not considered in cost evaluation due to lack of sufficient data. In addition, it is imperative to know the indirect costs associated with work loss hours and residual disability. This study did not account for the indefinite costs involving pain, distress, depression, suffering and stress caused by amputation. Also the indirect costs of amputation from the societal perspective resulted in disabilities, lost productivity on the part of the patient, or premature mortality were not taken into consideration. This cost analysis study has other limitations such as lack of information about the cost of outpatient care and use of resource for chronic diseases, like hospital or home-based rehabilitation after amputation or other diabetic complications. We attempted to remove uncertainty as much as possible by getting good quality data, to obtain a more accurate and standardised cost estimates from the hospital finance accounting. This study has a good external validly of results because all the amputation cases were managed in our national centre.

Conclusions {#s5}
===========

The economic burden associated with upper and lower extremity amputation-related hospitalisations is considerable. DM, advanced age and sociodemographic factors influence the incidence of amputation and its associated healthcare cost in Qatar.

The findings of this study will help to showcase the economic burden of amputation, which will be the basis for better management to reduce healthcare costs. There is an urgent need for effective standardised institutional screening protocol for minor and major extremity amputations among high-risk populations. Particularly, the effective approach to manage high-risk patients with diabetes includes an extensive patient education, early assessment and aggressive treatment by a multidisciplinary team. Furthermore, effective interventions may curb the otherwise impending clinical and economic burden of amputation in population with high prevalence of risk factors.
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